Revance Therapeutics, Inc. — Form D/A

Revance Therapeutics, Inc. of NEWARK, CA, a company, filed a Form D amendment with the SEC on 2010-11-18. The offering totals $36.2M, of which $36.2M was reported sold. Industry: Pharmaceuticals.

Offering

Issuer

Officers, directors & promoters (19)

NameRoleLocation
Ronald L EastmanDirectorNewark, CA
Frank L KungDirectorNewark, CA
Phyllis L GardnerDirectorNewark, CA
Jonathan L TunnicliffeDirectorNewark, CA
Daniel L BrowneDirectorNewark, CA
Daniel L BrowneExecutive OfficerNewark, CA
Vicente L TrellesDirectorNewark, CA
Robert L ByrnesDirectorNewark, CA
Jim L GlasheenDirectorNewark, CA
Vicente Daniel TrellesDirectorNewark, CA
Robert Daniel ByrnesDirectorNewark, CA
Phyllis Daniel GardnerDirectorNewark, CA
Frank Daniel KungDirectorNewark, CA
Jim Daniel GlasheenDirectorNewark, CA
Jonathan Daniel TunnicliffeDirectorNewark, CA
Ronald Daniel EastmanDirectorNewark, CA
L. Daniel BrowneDirectorNewark, CA
L. Daniel BrowneExecutive OfficerNewark, CA
Ron Daniel EastmanDirectorNewark, CA

Other filings by this issuer (10)

FiledFormOfferingSold
2013-10-23D$30.0M$10.0M
2013-02-22D$60.0M$5.0M
2013-01-09D/A$63.4M$63.4M
2012-09-14D/A$50.9M$50.9M
2011-10-06D$1.2M
2011-06-14D/A$45.0M$45.0M
2011-02-03D$15.0M$5.0M
2010-08-23D/A$34.4M$34.4M
2010-06-01D/A$33.4M$33.4M
2009-12-23D$25.6M$25.6M

More